Associated Papers
The OGG1 Ser326Cys polymorphism: molecular mechanisms of disease susceptibility and precision medicine applications.
Wang X et al.
Clinical Epigenetics, 2025
Mouse α-synuclein fibrils are structurally and functionally distinct from human fibrils associated with Lewy body diseases.
Sokratian A et al.
Science Advances, 2024
39485845 (PubMed )
Supplement: sciadv.adq3539_sm.pdf
Innate immune activation in neurodegenerative diseases.
Castro-Gomez S et al.
Immunity, 2024
Neuronal identity defines α-synuclein and tau toxicity.
Praschberger R et al.
Neuron, 2023
Single-Cell Transcriptomics of Parkinson's Disease Human In Vitro Models Reveals Dopamine Neuron-Specific Stress Responses.
Fernandes HJR et al.
Cell Reports, 2020
Current Evidence for a Bidirectional Loop Between the Lysosome and Alpha-Synuclein Proteoforms.
Wildburger NC et al.
Frontiers in Cell and Developmental Biology, 2020
Autonomic dysfunction in genetic forms of synucleinopathies.
Chelban V et al.
Movement Disorders : Official Journal of the Movement Disorder Society, 2018
Autosomal dominant Parkinson's disease and the route to new therapies.
Morris HR
Expert Review of Neurotherapeutics, 2007
Trypsin disrupts the trafficking of the human dopamine transporter by alpha-synuclein and its A30P mutant.
Wersinger C et al.
Biochemistry, 2004
Fe(II)-induced DNA damage in alpha-synuclein-transfected human dopaminergic BE(2)-M17 neuroblastoma cells: detection by the Comet assay.
Martin FL et al.
Journal of Neurochemistry, 2003
Select a paper to view details